{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:59:32Z","timestamp":1776916772788,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The optimal management of migraine involves care strategies that reflect what matters most to patients. This usually involves an assessment of treatment efficacy with respect to headache reduction, safety of prescribed medications and overall patient satisfaction and\/or improved quality of life. Traditionally, neurologists focus on objective measures such as monthly reductions to headache and migraine days from baseline. This is complemented with various patient reported outcome measures (PROMs) to quantify morbidity and treatment effect from the patient\u2019s perspective. We present a review of currently available headache specific PROMs to summarise the design, key attributes, response format, recall period and length of questionnaires.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A literature search was conducted using OVID Medline, Embase and Cochrane Library. The search strategy involved: (satisfaction OR patient satisfaction OR efficacy OR effectiveness) AND (disability OR morbidity OR burden OR severity OR impact OR patient reported outcomes OR PROMs OR outcome measures OR MIDAS OR HIT6 OR HDI OR MSQ OR MIG-SCOG OR Eq.\u00a05D OR WPAI OR PGIC OR quality of life or QOL) AND (migraine OR chronic migraine OR headache OR primary headache OR cephalalgia OR headache disorder). A total of 16,024 articles returned. Removal of duplicates (<jats:italic>n<\/jats:italic>\u2009=\u2009111), title and abstract screening (<jats:italic>n<\/jats:italic>\u2009=\u200915,853) and subsequent full text analysis (<jats:italic>n<\/jats:italic>\u2009=\u200919), left 41 articles. Reviewer comments led to addition of further 3 articles to our review. In total, of 44 included articles there were 20 headache-specific PROMs analysed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results and conclusion<\/jats:title>\n            <jats:p>Our findings show that there is a significant lack of patient involvement in creation of headache PROMs thus there may be a gap between perceived treatment efficacy from the perspective of neurologists and that of patients. We suggest future assessment of migraine treatment efficacy considers what is important to the patient as a priority, in an effort to improve satisfaction with care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10194-025-02019-x","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:10:11Z","timestamp":1744215011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prioritising patient involvement in patient reported outcome measures\u2013 a PROMising way to improve headache care"],"prefix":"10.1186","volume":"26","author":[{"given":"Lakshini","family":"Gunasekera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"C. Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elspeth","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"J. O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2019_CR1","doi-asserted-by":"crossref","unstructured":"Packard R (1979) What does the headache patient want. Headache","DOI":"10.1111\/j.1526-4610.1979.hed1907370.x"},{"key":"2019_CR2","unstructured":"GBD 2021 Nervous System Disorders Collaborators Global, regional, and National burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. (1474\u20134465 (Electronic))."},{"key":"2019_CR3","unstructured":"Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G et al Hallmarks of primary headache: part 1 - migraine. (1129\u20132377 (Electronic))."},{"key":"2019_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ddr.20207","volume":"68","author":"KS Anand","year":"2007","unstructured":"Anand KS, Sharma S (2007) Quality of life in migraine. Drug Dev Res 68:403\u2013411","journal-title":"Drug Dev Res"},{"key":"2019_CR5","doi-asserted-by":"crossref","unstructured":"Kim B-K, Chu MK, Yu SJ, Dell\u2019Agnello G, Han JH, Cho S-J (2021) Burden of migraine and unmet needs from the patients\u2019 perspective: a survey across11 specialized headache clinics in Korea. J Headache Pain","DOI":"10.1186\/s10194-021-01250-6"},{"key":"2019_CR6","doi-asserted-by":"crossref","unstructured":"Davies PTG, Glynn CJ, Kadry MA (2003) Expectations of patients attending a combined headache clinic. J Headache Pain.:79\u201382","DOI":"10.1007\/s10194-003-0035-8"},{"key":"2019_CR7","first-page":"147","volume":"5","author":"JM Guiu","year":"2012","unstructured":"Guiu JM, Caloto MT, Nocea G (2012) Comparison of expected outcomes between patients and neurologists using Kano\u2019s methodology in symptomatic migraine treatment. Patient 5:147\u2013162","journal-title":"Patient"},{"issue":"7","key":"2019_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1177\/0333102417731348","volume":"38","author":"KL Haywood","year":"2018","unstructured":"Haywood KL, Mars TS, Potter R, Patel S, Matharu M, Underwood M (2018) Assessing the impact of headaches and the outcomes of treatment: a systematic review of patient-reported outcome measures (PROMs). Cephalalgia 38(7):1374\u20131386","journal-title":"Cephalalgia"},{"key":"2019_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/head.14706","volume":"64","author":"MHJ Hazewinkel","year":"2024","unstructured":"Hazewinkel MHJ, Gfrerer L, Ashina S, Austen WG, Klassen AF, Pusic A et al (2024) Readability analysis and concept mapping of proms used for headache disorders. Headache 64:410\u2013423","journal-title":"Headache"},{"key":"2019_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/11592170-000000000-00000","volume":"5","author":"DM Turner-Bowker","year":"2012","unstructured":"Turner-Bowker DM, Saris-Baglama R, DeRosa MA, Paulsen CA (2012) Cognitive testing and readability of an item bank for measuring the impact of headache on Health-Related quality of life. Patient 5:89\u201399","journal-title":"Patient"},{"key":"2019_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/B978-0-12-823357-3.00022-7","volume":"199","author":"A Hareendran","year":"2024","unstructured":"Hareendran A, Mannix S (2024) Outcome measures for migraine: measuring the impact of migraine and results of migraine treatment. Handb Clin Neurol 199:303\u2013328","journal-title":"Handb Clin Neurol"},{"key":"2019_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/head.14664","volume":"64","author":"R Mangrum","year":"2024","unstructured":"Mangrum R, Bryant AL, Gerstein MT, McCarrier KP, Houts CR, McGinley JS et al (2024) The impacts of migraine on functioning: results from two qualitative studies of people living with migraine. Headache 64:156\u2013171","journal-title":"Headache"},{"key":"2019_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/head.13708","volume":"60","author":"S Munjal","year":"2019","unstructured":"Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW et al (2019) Most bothersome symptom in persons with migraine: results from the migraine in America symptoms and treatment (MAST) study. Headache 60:416\u2013429","journal-title":"Headache"},{"key":"2019_CR14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/03331024211006048","volume":"41","author":"H Pohl","year":"2021","unstructured":"Pohl H, Benemei S, Garcia-Azorin D, Dixon J, Huzzey E, Ferrari MD (2021) Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments. Cephalalgia 41:1027\u20131032","journal-title":"Cephalalgia"},{"key":"2019_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s11136-022-03279-9","volume":"32","author":"EM Buchanan","year":"2023","unstructured":"Buchanan EM, Manley HR, Sly JS, Cady RJ, Wikowsky A, Cunningham AL (2023) Development of the functional assessment of migraine scale using a patient guided approach. Qual Life Res 32:867\u2013879","journal-title":"Qual Life Res"},{"key":"2019_CR16","doi-asserted-by":"crossref","unstructured":"Smelt AFH, Louter MA, Kies DA, Blom JW, Terwind GM, Heijden, GJMGvd et al (2014) What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment?? Results of a Delphi study. PLoS ONE.;9(6)","DOI":"10.1371\/journal.pone.0098933"},{"key":"2019_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1046\/j.1468-2982.2000.00082.x","volume":"20","author":"G Davies","year":"2000","unstructured":"Davies G, Santanello N, Lipton R (2000) Determinants of patient satisfaction with migraine therapy. Cephalalgia 20:554\u2013560","journal-title":"Cephalalgia"},{"key":"2019_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/head.14067","volume":"61","author":"CR Houts","year":"2021","unstructured":"Houts CR, McGinley JS, Nishida TK, Buse DC, Wirth RJ, Dodick DW et al (2021) Systematic review of outcomes and endpoints in acute migraine clinical trials. Headache 61:263\u2013275","journal-title":"Headache"},{"key":"2019_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10194-008-0052-8","volume":"9","author":"F Antonaci","year":"2008","unstructured":"Antonaci F, Sances G, Guaschino E, Cillis ID, Bono G, Nappi G (2008) Meeting patient expectations in migraine treatment: what are the key endpoints? J Headache Pain 9:207\u2013213","journal-title":"J Headache Pain"},{"key":"2019_CR20","doi-asserted-by":"crossref","unstructured":"Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P (2021) In Search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real world evidence study. J Headache Pain.;22(151)","DOI":"10.1186\/s10194-021-01366-9"},{"key":"2019_CR21","doi-asserted-by":"crossref","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Montisano DA, Antolak M, Bighiani F, Cammarota F, Cetta I et al The impact of primary headaches on disability outcomes: a literature review and meta-analysis to inform future iterations of the global burden of disease study. 2024(1129\u20132377 (Electronic)).","DOI":"10.1186\/s10194-024-01735-0"},{"key":"2019_CR22","doi-asserted-by":"crossref","unstructured":"Patrick DL, Martin ML, Bushnell DM, Pesa J (2003) Measuring satisfaction with migraine treatment: expectations, importance, outcomes, and global ratings. Clin Ther.;25","DOI":"10.1016\/S0149-2918(03)80345-4"},{"key":"2019_CR23","doi-asserted-by":"crossref","unstructured":"Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH et al (2015) Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Healthc Epidemiol.;61","DOI":"10.1093\/cid\/civ495"},{"key":"2019_CR24","doi-asserted-by":"crossref","unstructured":"Doernberg SB (2022) Desirability of outcome ranking and quality of life measurement for antimicrobial ressearch in organ transplantation. Transpl Infect Disease.;24","DOI":"10.1111\/tid.13888"},{"key":"2019_CR25","first-page":"1","volume":"1","author":"L Vivash","year":"2023","unstructured":"Vivash L, Johns H, O\u2019Brien TJ, Churilov L (2023) The adaptation of the desirability of outcome ranking for interventional clinical trials in epilepsy: a novel consumer-led outcome measure. Epilepsia 1:1\u20138","journal-title":"Epilepsia"},{"key":"2019_CR26","doi-asserted-by":"crossref","unstructured":"Vivash L, Johns H, Churilov L, MacPhail S, Casillas-Espinosa P, Malpas C et al (2023) Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant Temporal lobe epilepsy: the select study protocol. BMJ Open.;13(10)","DOI":"10.1136\/bmjopen-2023-075888"},{"key":"2019_CR27","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/WNL.44.5.837","volume":"44","author":"GP Jacobson","year":"1994","unstructured":"Jacobson GP, Ramadan NM, Aggarwal SK, Newman CK (1994) The Henry Ford hospital headache disability inventory HDI. Neurology 44:837\u2013842","journal-title":"Neurology"},{"key":"2019_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.math.2007.09.006","volume":"14","author":"N Ken","year":"2009","unstructured":"Ken N, Anthony Q (2009) Development of a headache-specific disability questionnaire for patients attending physiotherapy. Man Therap 14:45\u201351","journal-title":"Man Therap"},{"key":"2019_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963\u2013974","journal-title":"Qual Life Res"},{"key":"2019_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/WNL.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN et al (1999) An international study to assess reliability of the migraine disability assessment (MIDAS) score. Neurology 53:988\u2013994","journal-title":"Neurology"},{"key":"2019_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","volume":"40","author":"BC Martin","year":"2000","unstructured":"Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ et al (2000) Validity and reliability of the Migraine-Specific quality of life questionnaire (MSQ version 2.1). Headache 40:204\u2013215","journal-title":"Headache"},{"key":"2019_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2165\/00044011-199815050-00006","volume":"15","author":"SP McKenna","year":"1998","unstructured":"McKenna SP, Doward LC, Davey KM (1998) The development and psychometric properties of the MSQOL. Clin Drug Investig 15:413\u2013423","journal-title":"Clin Drug Investig"},{"key":"2019_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1046\/j.1526-4610.2001.111006402.x","volume":"41","author":"JA Cramer","year":"2001","unstructured":"Cramer JA, Silberstein SD, Winner P (2001) Development and validation of the headache needs assessment (HANA) survey. Headache 41:402\u2013409","journal-title":"Headache"},{"issue":"9","key":"2019_CR34","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1177\/0333102409354323","volume":"30","author":"C Andree","year":"2009","unstructured":"Andree C, Vaillant M, Barre J, Katsarava Z, Lainez JM, Lair M-L et al (2009) Development and validation of the EUROLIGHT questionnaire to evaluate the burden of primary headache disorders in Europe. Cephalalgia 30(9):1082\u20131100","journal-title":"Cephalalgia"},{"key":"2019_CR35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1526-4610.2012.02099.x","volume":"52","author":"CD Coon","year":"2012","unstructured":"Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK (2012) The development of a survey to measure completeness of response to migraine therapy. Headache 52:550\u2013572","journal-title":"Headache"},{"issue":"7","key":"2019_CR36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1185\/030079904125004079","volume":"20","author":"AJ Dowson","year":"2004","unstructured":"Dowson AJ, Tepper SJ, Baos V, Baudet F, D\u2019Amico D, Kilminster S (2004) Identifying patients who require a change in their current acute migraine treatment: the migraine assessment of current therapy (Migraine-ACT) questionnaire. Curr Med Res Opin 20(7):1125\u20131135","journal-title":"Curr Med Res Opin"},{"key":"2019_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1046\/j.1526-4610.2002.02230.x","volume":"42","author":"ML Chatterton","year":"2002","unstructured":"Chatterton ML, Lofland JH, Shechter A, Curtice WS, Hu H, Lenow J et al (2002) Reliability and validity of the migraine therapy assessment questionnaire. Headache 42:1006\u20131015","journal-title":"Headache"},{"key":"2019_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Kolodner K, Bigal ME, Valade D, Lainez MJA, Pascual J et al (2009) Validity and reliability of the Migraine-Treatment optimisation questionnaire. Cephalalgia 29:751\u2013759","journal-title":"Cephalalgia"},{"key":"2019_CR39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1526-4610.2006.00289.x","volume":"46","author":"DA Revicki","year":"2006","unstructured":"Revicki DA, Kimel M, Beusterin K, Kwong JW, Varner JA, Ames MH et al (2006) Validation of the revised patient perception of migraine questionnaire: measuring satisfaction with acute migraine treatment. Headache 46:240\u2013252","journal-title":"Headache"},{"key":"2019_CR40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1526-4610.2012.02156.x","volume":"52","author":"JE Magnusson","year":"2012","unstructured":"Magnusson JE, Riess CM, Becker WJ (2012) Modification of the SF-36 for a headache population changes patient-reported health status. Headache 52:993\u20131004","journal-title":"Headache"},{"key":"2019_CR41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware","year":"1996","unstructured":"Ware J, Kosinski M, Keller SD (1996) A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220\u2013233","journal-title":"Med Care"},{"key":"2019_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"M Buxton","year":"1990","unstructured":"Buxton M, O\u2019Hanlon M, Rushby J, Pekurinen M, Sintonen H, Bjork S et al (1990) EuroQOL - a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"key":"2019_CR43","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1177\/0333102411408359","volume":"31","author":"R Gil-Gouveia","year":"2011","unstructured":"Gil-Gouveia R, Oliveira AG, Martins IP (2011) A subjective cognitive impairments scale for migraine attacks. The MIG-SCOG: development and validation. Cephalalgia 31:984\u2013991","journal-title":"Cephalalgia"},{"key":"2019_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1023\/A:1008920510098","volume":"8","author":"DJ Lerner","year":"1999","unstructured":"Lerner DJ, Amick BC, Malspeis S, Rogers WH, Santanello NC, Gerth WC et al (1999) The migraine work and productivity loss questionnaire: concepts and design. Qual Life Res 8:699\u2013710","journal-title":"Qual Life Res"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02019-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02019-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02019-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:05:13Z","timestamp":1744250713000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02019-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02019-x","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LG, TOB, NK and HB have no conflicts of interest to declare. JCR reports in the last 36 months he has received honoraria for educational presentations for Abbvie, Novartis and Viatris. He has served on medical advisory boards for Pfizer, Viatris and Lilly. His institution has received funding for research grants, clinical trials and projects supported by the International Headache Society, Brain Foundation, Lundbeck, Abbvie, Pfizer and Aeon.EH has served on advisory boards for Sanofi-Genzyme, Novartis, Teva, Eli Lilly, Allergan, Lundbeck, been involved in clinical trials sponsored by Novartis, Teva, Xalud, Cerecin, and has received payment for educational presentations from Allergan, Teva, Eli Lilly and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}